Close
Close
Treatment News

Benitec to present OPMD data at the American Society of Gene and Cell Therapy Meeting

2.5
2.5 from 2 votes
Tuesday, May 15, 2018

Sydney, Australia - Benitec Biopharma Limited (ASX:BLT; NASDAQ:BNTC; NASDAQ:BNTCW) announced that data from its oculopharyngeal muscular dystrophy (OPMD) program will be presented at the American Society of Gene and Cell Therapy (ASGCT) meeting being held in Chicago on May 16-19.

The presentation provides the new nonclinical efficacy data on BB-301, the single vector system which uses DNA directed RNA interference (ddRNAi) to silence expression of the mutant gene associated with OPMD, while simultaneously adding back a copy of the normal version of the same gene to restore gene function. BB-301 is the clinical candidate that Benitec is progressing towards the clinic.

The 21st Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) is being held May 16-19 at the Hilton Chicago, Chicago, USA. Details of the oral presentation are noted below:

Date: Thursday 17 May at 4:15pm CDT (Oral Presentation)

Title: BB-301: A Single “Silence and Replace” AAV-Based Vector for the
Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)

Presenter: David Suhy, PhD, Chief Scientific Officer

A copy of the full presentation will be posted to the Presentations and Publications section of the
Company's website following the talk. The abstract is detailed below.

The Company will also be hosting an OPMD conference call and webcast for investors and analysts on 15 May 2018 at 4:30pm U.S. EDT / 16 May 2018 at 6:30am Australian EST. The presentation will provide a detailed overview of oculopharyngeal muscular dystrophy (OPMD), Benitec's BB-301 gene therapy construct, as well as the associated market opportunity and product pipeline. For more information and to register for the webinar, please contact the persons below or visit https://register.gotowebinar.com/register/8868899774141644803. The event will also be recorded and available for on-demand viewing in the For Investors section at www.benitec.com.

Contacts:
Benitec Biopharma
Suite 1201, 99 Mount Street
North Sydney, NSW 2060 Australia
P. +61 2 9555 6986
E. info@benitec.com

Source: Benitec Biopharma Limited
2.5
2.5 from 2 votes
Free Newsletter
Videos
by Abidemi Uruejoma
9 views
by Abidemi Uruejoma
40 views
by Abidemi Uruejoma
55 views
by Abidemi Uruejoma
78 views